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Resection of liver metastases from colorectal carcinoma (CRC)
is associated with 5-year survival rates of 30–40%, with the
possibility of cure, even in the absence of systemic therapy.
This demonstration of a local therapy improving outcomes
for ‘oligo-metastatic’ CRC is well accepted. Long-term survi-
vors have also been reported following resection of liver
metastases from sarcoma, renal-cell carcinoma, breast can-
cer and melanoma, with 5-year survival rates of 23–36% in a
series of non-CRC liver metastases. Resection of neuroendo-
crine liver metastases has also been associated with favour-
able survival.
Stereotactic body radiation therapy (SBRT) is an attractive
option for patients with liver metastases. Liver SBRT re-
quires a planning computed tomography (CT) simulation
scan with intravenous (IV) contrast for target definition.
Multimodal imaging with contrast-enhanced magnetic reso-
nance imaging (MRI) or positron emission tomography (PET)
may improve target delineation. Breathing-related liver mo-
tion should be assessed by respiratory-correlated (or 4D) CT,
cine-MRI or 2D kV fluoroscopy to determine appropriate
planning target volume (PTV) margins. Highly conformal
dose distributions are desirable using multiple beams or
arcs in coplanar or non-coplanar geometries. The nominal
prescribed dose should reflect the isodose that encompasses
the PTV (or 95% of the PTV) with hotspots within the PTV.
Immobilization of the liver using controlled breath holds,
shallow breathing, abdominal compression and gating of
the RT (radiation therapy) beam during specified phases of
the respiratory cycle, medications and tumour tracking of
implanted fiducial markers may help reduce the adverse ef-
fects of breathing motion. Image-guided RT (IGRT) based on
orthogonal imaging, ultrasound or volumetric imaging such
as MV or kV cone beam CT, is required at every fraction in
order to reduce PTV margins for setup uncertainty. MR IGRT
is an area of active research that may benefit patients
requiring liver SBRT.Advantages of SBRT include increased convenience for
patients. Furthermore, there are preclinical data demon-
strating dose-per-fraction effects (e.g. endothelial and
immune effects), with a threshold of approximately 8 Gray
(Gy). Clinical experience in SBRT for liver metastases is
rapidly increasing.2. Methods
Updated results from Princess Margaret Cancer Centre
phase I/II studies of SBRT for liver metastases are
presented, as well as a review of previously published
SBRT studies and consensus statements of radiation ther-
apy for liver metastases.3. Results
In our centre in Toronto, a phase I/II study of individua-
lised IGRT-guided SBRT was conducted in 107 patients
with 172 unresectable or medically inoperable liver metas-
tases from CRC, breast cancer or other primary sites [1].
The median tumour volume was 75 ml. Extrahepatic dis-
ease was present in 40 patients (43%), and 75% had re-
ceived prior systemic therapy. Patients were treated with
six-fraction SBRT (median dose 42 Gy, range 24–48 Gy).
No radiation-induced liver toxicity was observed. Median
survival was 18.1 months. The presence of extrahepatic
disease was associated with worse survival. Prognostic
factors for improved local control included breast primary
site, dose and tumour volume. Some patients with CRC or
breast cancer liver metastases are alive with no progres-
sive disease more than 5 years post-SBRT.
In a subset of patients from the Toronto cohort with
unresectable liver metastases who had kV cone-beam CT
scans at each fraction, the cone-beam CTs were used in
combination with deformable image registration to deter-
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scribed dose). Accumulated minimum doses to the GTV
(gross tumour volume) of <35 Gy, 35–45 Gy and >45 Gy, in
six fractions were associated with 18-month local control
of 33%, 55% and 83%, respectively. The dose–response rela-
tionship was steeper for accumulated dose compared with
prescribed dose.
Most published SBRT studies have prescribed doses in the
range 30–60 Gy in 1–6 fractions, for <5 metastases, with max-
imal tumour sizes 66 cm. CRC liver metastases are the most
frequent tumour type. However, an increasing number of pa-
tients with liver metastases from breast and lung cancer are
being included in recent SBRT series. In the published series,
survival rates have been better than those expected following
systemic therapy alone. Toxicity is uncommon as long as en-
ough uninvolved liver can be spared from radiation therapy
(e.g. >700 ml receiving 15 Gy in three fractions or mean liver
dose <18 Gy in six fractions). Local control of the irradiated li-
ver metastases at 1 year ranges from 67% to 100%. The med-
ian survival of patients treated with SBRT ranges from 18 to
37 months, with the best outcomes seen in a more recent
series.
A dose response has been observed in most series, with an
increased chance of sustained local control (80–90% at
2 years) when doses >42 Gy in three fractions are used. Local
control is also improved in patients with metastases <3 cm in
maximal size and in breast cancer metastases compared to
colorectal cancer metastases.
In a pooled analysis of SBRT for CRC metastases [2], dose
was the only significant prognostic factor for local control
and extra-hepatic disease and local recurrence were associ-
ated with impaired survival. A dose of 48–51 Gy in three frac-
tions was estimated to be associated with a 1-year local
control rate of 90%.
An international subcommittee – with members from the
American Society for Radiation Oncology (ASTRO), the Euro-
pean Society for Therapeutic Radiology and Oncology (ES-
TRO), the Canadian Association of Radiation Oncology
(CARO) and the Trans-Tasman Radiation Oncology Group
(TROG) – led by Hoyer et al [3] developed a consensus state-
ment of liver metastases radiation therapy. Ideal candidates
for SBRT were described as patients with good performance
status (ECOG 0–1), possessing adequate hepatic function, with
no extrahepatic disease, having ideally 65 liver metastases
and an uninvolved liver volume P700 ml. As outcomes are
best following higher-dose SBRT, most suitable patients in-
clude those with a focal distribution of metastases, at least
1 cm from luminal gastrointestinal organs. Breast cancer
metastases appear more sensitive than CRC metastases.
The consensus statement described uncommon toxicity in
the liver, with increased risk in patients re-irradiated and/or
with prior liver disease. Luminal gastrointestinal toxicity
and chest wall and rib fractures have also occasionally been
seen. Of note, the consensus statement briefly reviewed
non-SBRT methods of delivering high-dose radiation therapyto liver metastases, including conformal radiation therapy,
selective internal radiation therapy (e.g. hepatic arterial deliv-
ery of yttrium) and interstitial or intraluminal brachytherapy.
In addition, patients with diffuse symptomatic liver metasta-
ses were highlighted as a population largely understudied, in
whom low-dose palliative whole-liver radiation therapy may
be of benefit. In a pilot study of 20 patients with symptoms
from diffuse liver metastases at the Princess Margaret Cancer
Centre, approximately 50% of the patients had a patient-re-
ported benefit in pain or discomfort at 1 month following
8 Gy in one fraction. Based on this, a phase III study of simple
palliative radiation therapy compared to best supportive care
is planned (HE.1, through the National Cancer Institute of
Canada Clinical Trials Group).4. Conclusions
SBRT is a promising treatment for patients with focal ‘oligo’
liver metastases. The most suitable patients with liver metas-
tases are those with three or fewer metastatic tumours, each
<6 cm, with no extrahepatic disease and with metastases at
least 2 cm from the luminal gastrointestinal tissues. More re-
search is required regarding optimal dose-per-fraction and
mechanisms, as well as the most appropriate patient
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